Cargando…

Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study

BACKGROUND: The urine lipoarabinomannan (LAM) strip test has been suggested as a new point-of-care test for active tuberculosis (TB) among human immunodeficiency virus (HIV) infected individuals. It has been questioned if infections with nontuberculous mycobacteria (NTM) affect assay specificity. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Qvist, Tavs, Johansen, Isik S, Pressler, Tania, Høiby, Niels, Andersen, Aase B, Katzenstein, Terese L, Bjerrum, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260379/
https://www.ncbi.nlm.nih.gov/pubmed/25471640
http://dx.doi.org/10.1186/s12879-014-0655-4
_version_ 1782348173717536768
author Qvist, Tavs
Johansen, Isik S
Pressler, Tania
Høiby, Niels
Andersen, Aase B
Katzenstein, Terese L
Bjerrum, Stephanie
author_facet Qvist, Tavs
Johansen, Isik S
Pressler, Tania
Høiby, Niels
Andersen, Aase B
Katzenstein, Terese L
Bjerrum, Stephanie
author_sort Qvist, Tavs
collection PubMed
description BACKGROUND: The urine lipoarabinomannan (LAM) strip test has been suggested as a new point-of-care test for active tuberculosis (TB) among human immunodeficiency virus (HIV) infected individuals. It has been questioned if infections with nontuberculous mycobacteria (NTM) affect assay specificity. We set forth to investigate if the test detects LAM in urine from a Danish cystic fibrosis (CF) population characterized by a high NTM prevalence and negligible TB exposure. METHOD: Patients followed at the Copenhagen CF Center were comprehensively screened for pulmonary NTM infection between May 2012 and December 2013. Urine samples were tested for LAM using the 2013 Determine™ TB LAM Ag strip test. RESULTS: Three-hundred and six patients had a total of 3,322 respiratory samples cultured for NTM and 198 had urine collected (65%). A total of 23/198 (12%) had active pulmonary NTM infection. None had active TB. The TB-LAM test had an overall positive rate of 2.5% applying a grade 2 cut-point as positivity threshold, increasing to 10.6% (21/198) if a grade 1 cut-point was applied. Among patients with NTM infection 2/23 (8.7%) had a positive LAM test result at the grade 2 cut-point and 9/23 (39.1%) at the grade 1 cut -point. Test specificity for NTM diagnosis was 98.3% and 93.1 for grade 2 and 1 cut-point respectively. CONCLUSIONS: This is the first study to assess urine LAM detection in patients with confirmed NTM infection. The study demonstrated low cross-reactivity due to NTM infection when using the recommended grade 2 cut-point as positivity threshold. This is reassuring in regards to interpretation of the LAM test for TB diagnosis in a TB prevalent setting. The test was not found suitable for NTM detection among patients with CF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0655-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4260379
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42603792014-12-09 Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study Qvist, Tavs Johansen, Isik S Pressler, Tania Høiby, Niels Andersen, Aase B Katzenstein, Terese L Bjerrum, Stephanie BMC Infect Dis Research Article BACKGROUND: The urine lipoarabinomannan (LAM) strip test has been suggested as a new point-of-care test for active tuberculosis (TB) among human immunodeficiency virus (HIV) infected individuals. It has been questioned if infections with nontuberculous mycobacteria (NTM) affect assay specificity. We set forth to investigate if the test detects LAM in urine from a Danish cystic fibrosis (CF) population characterized by a high NTM prevalence and negligible TB exposure. METHOD: Patients followed at the Copenhagen CF Center were comprehensively screened for pulmonary NTM infection between May 2012 and December 2013. Urine samples were tested for LAM using the 2013 Determine™ TB LAM Ag strip test. RESULTS: Three-hundred and six patients had a total of 3,322 respiratory samples cultured for NTM and 198 had urine collected (65%). A total of 23/198 (12%) had active pulmonary NTM infection. None had active TB. The TB-LAM test had an overall positive rate of 2.5% applying a grade 2 cut-point as positivity threshold, increasing to 10.6% (21/198) if a grade 1 cut-point was applied. Among patients with NTM infection 2/23 (8.7%) had a positive LAM test result at the grade 2 cut-point and 9/23 (39.1%) at the grade 1 cut -point. Test specificity for NTM diagnosis was 98.3% and 93.1 for grade 2 and 1 cut-point respectively. CONCLUSIONS: This is the first study to assess urine LAM detection in patients with confirmed NTM infection. The study demonstrated low cross-reactivity due to NTM infection when using the recommended grade 2 cut-point as positivity threshold. This is reassuring in regards to interpretation of the LAM test for TB diagnosis in a TB prevalent setting. The test was not found suitable for NTM detection among patients with CF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0655-4) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-04 /pmc/articles/PMC4260379/ /pubmed/25471640 http://dx.doi.org/10.1186/s12879-014-0655-4 Text en © Qvist et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Qvist, Tavs
Johansen, Isik S
Pressler, Tania
Høiby, Niels
Andersen, Aase B
Katzenstein, Terese L
Bjerrum, Stephanie
Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title_full Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title_fullStr Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title_full_unstemmed Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title_short Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study
title_sort urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the danish cystic fibrosis cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260379/
https://www.ncbi.nlm.nih.gov/pubmed/25471640
http://dx.doi.org/10.1186/s12879-014-0655-4
work_keys_str_mv AT qvisttavs urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT johansenisiks urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT presslertania urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT høibyniels urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT andersenaaseb urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT katzensteinteresel urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy
AT bjerrumstephanie urinelipoarabinomannanpointofcaretestinginpatientsaffectedbypulmonarynontuberculousmycobacteriaexperiencesfromthedanishcysticfibrosiscohortstudy